The extensive expression of BAFF‐R in B‐cell malignancies, along with its crucial role in tumor cell survival, makes BAFF‐R an appealing target for CAR T‐cell therapy in CLL.33 This evidence concerns the gene TNFRSF13C and neoplasm.